Market By Type, Technology, Age Group, Delivery Mode And Geography | Forecast 2019-2028
An analysis by Triton Market Research has concluded that the European influenza vaccines market is expected to grow at a CAGR of 6.16% during the forthcoming period 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries evaluated in the Europe influenza vaccines market are:
• Italy
• The United Kingdom
• Germany
• Russia
• France
• Spain
• Rest of Europe
European countries lack a unified vaccination policy. Thus, policies differ from country to country within the region. However, the ECDC (European Centre for Disease Prevention and Control) and the WHO (World Health Organization) provide some standard guidelines for the member states. The EURO policy framework targets the prevention of diseases by vaccination. Europe has been the leader in the field of vaccines for more than ten years, in terms of exports, research & development and vaccine production. The local market players in the region have now expanded their presence into other geographical regions. These developments indicate an increase in the growth of the influenza vaccines market in Europe.
In the United Kingdom, the universal childhood influenza vaccine program was launched in 2018-2019 with a live attenuated influenza vaccine. The program was offered to children of 2 and 3-year-olds throughout the UK, and to the children of Reception, Year 1, 2, 3, 4 and 5. Likewise, in Scotland and Northern Ireland, the vaccination was provided to children in primary school. These favorable initiatives are indicating considerable growth in the influenza vaccines market in the UK in the forecasted period. In Italy, the people who are at the risk of contracting the virus, like children, pregnant women, health workers and the aged, are urged to get vaccinated by the health ministry. This factor is likely to aid the adoption of the vaccines, and thereby help the growth of the European influenza vaccines market.
Novartis is a company that is involved in research, development, manufacturing and marketing of different healthcare products. It operates in three major business segments, innovative medicines, Sandoz and Alcon. FluQuadri is an influenza vaccine provided by the company. It is headquartered in Basel, Switzerland.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE INFLUENZA VACCINES MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. QUADRIVALENT IS THE DOMINANT TYPE OF INFLUENZA VACCINE
2.2.2. INJECTION IS FASTEST-GROWING DELIVERY MODE
2.2.3. CELL-BASED TECHNOLOGY IS RAPIDLY GROWING TECHNOLOGY IN THE MARKET
2.2.4. ADULT AGE GROUP IS MAJORLY CONTRIBUTING IN THE MARKET
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE
2.3.3. BARGAINING POWER OF SUPPLIERS
2.3.4. BARGAINING POWER OF BUYERS
2.3.5. INTENSITY OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. MARKET DRIVERS
2.6.1. ADVANCEMENT IN TECHNOLOGY
2.6.2. INITIATIVES TAKEN UP BY THE GOVERNMENT
2.7. MARKET RESTRAINTS
2.7.1. HIGH COST OF DEVELOPMENT
2.8. MARKET OPPORTUNITIES
2.8.1. GROWTH IN THE CASES OF INFLUENZA
2.9. MARKET CHALLENGES
2.9.1. COMPLEX DEVELOPMENT PROCESS
3. INFLUENZA VACCINES MARKET OUTLOOK - BY TYPE
3.1. QUADRIVALENT VACCINE
3.2. TRIVALENT VACCINE
4. INFLUENZA VACCINES MARKET OUTLOOK - BY TECHNOLOGY
4.1. EGG-BASED TECHNOLOGY
4.2. CELL-BASED TECHNOLOGY
5. INFLUENZA VACCINES MARKET OUTLOOK - BY AGE GROUP
5.1. PEDIATRIC AGE GROUP
5.2. ADULT AGE GROUP
6. INFLUENZA VACCINES MARKET OUTLOOK - BY DELIVERY MODE
6.1. INJECTION
6.2. NASAL SPRAY
7. INFLUENZA VACCINES MARKET – EUROPE
7.1. UNITED KINGDOM
7.2. GERMANY
7.3. FRANCE
7.4. SPAIN
7.5. ITALY
7.6. RUSSIA
7.7. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. MERCK SHARP & DOHME CORP
8.2. NOVARTIS AG
8.3. PFIZER INC
8.4. SANOFI
8.5. BIODIEM
8.6. EMERGENT BIOSOLUTIONS INC
8.7. F. HOFFMANN-LA ROCHE LTD
8.8. GLAXOSMITHKLINE PLC
8.9. ABBOTT
8.10. CSL LIMITED
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.1.1. OBJECTIVES OF STUDY
9.1.2. SCOPE OF STUDY
9.2. SOURCES OF DATA
9.2.1. PRIMARY DATA SOURCES
9.2.2. SECONDARY DATA SOURCES
9.3. RESEARCH METHODOLOGY
9.3.1. EVALUATION OF PROPOSED MARKET
9.3.2. IDENTIFICATION OF DATA SOURCES
9.3.3. ASSESSMENT OF MARKET DETERMINANTS
9.3.4. DATA COLLECTION
9.3.5. DATA VALIDATION & ANALYSIS
TABLE 1: EUROPE INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: EUROPE INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 4: EUROPE INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 5: EUROPE INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 6: EUROPE INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 7: EUROPE INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: EUROPE INFLUENZA VACCINES MARKET, BY SOURCE, 2019 & 2028 (IN %)
FIGURE 2: EUROPE QUADRIVALENT INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 3: EUROPE INJECTION DELIVERY MODEL MARKET, 2019-2028 (IN $ MILLION)
FIGURE 4: EUROPE CELL-BASED TECHNOLOGY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 5: EUROPE ADULT AGE GROUP MARKET, 2019-2028 (IN $ MILLION)
FIGURE 6: PORTER’S FIVE FORCE ANALYSIS
FIGURE 7: MARKET ATTRACTIVENESS INDEX
FIGURE 8: EUROPE INFLUENZA VACCINES MARKET, BY QUADRIVALENT VACCINE, 2019-2028 (IN $ MILLION)
FIGURE 9: EUROPE INFLUENZA VACCINES MARKET, BY TRIVALENT VACCINES, 2019-2028 (IN $ MILLION)
FIGURE 10: EUROPE INFLUENZA VACCINES MARKET, BY EGG-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 11: EUROPE INFLUENZA VACCINES MARKET, BY CELL-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: EUROPE INFLUENZA VACCINES MARKET, BY PEDIATRIC AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 13: EUROPE INFLUENZA VACCINES MARKET, BY ADULT AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 14: EUROPE INFLUENZA VACCINES MARKET, BY INJECTION, 2019-2028 (IN $ MILLION)
FIGURE 15: EUROPE INFLUENZA VACCINES MARKET, BY NASAL SPRAY, 2019-2028 (IN $ MILLION)
FIGURE 16: EUROPE INFLUENZA VACCINES MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 17: UNITED KINGDOM INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: GERMANY INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: FRANCE INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 20: SPAIN INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 21: ITALY INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 22: RUSSIA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 23: REST OF EUROPE INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)